Mirabaud & Cie SA Has $6.60 Million Stock Holdings in Procter & Gamble Company (The) $PG

Mirabaud & Cie SA trimmed its stake in shares of Procter & Gamble Company (The) (NYSE:PG) by 12.7% in the fourth quarter, Holdings Channel.com reports. The fund owned 46,076 shares of the company’s stock after selling 6,730 shares during the quarter. Procter & Gamble makes up approximately 2.1% of Mirabaud & Cie SA’s investment portfolio, making the stock its 12th biggest position. Mirabaud & Cie SA’s holdings in Procter & Gamble were worth $6,603,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its position in shares of Procter & Gamble by 51.5% in the 4th quarter. Brighton Jones LLC now owns 40,068 shares of the company’s stock worth $6,717,000 after purchasing an additional 13,617 shares during the period. Taylor Financial Group Inc. increased its position in shares of Procter & Gamble by 10.6% during the first quarter. Taylor Financial Group Inc. now owns 2,891 shares of the company’s stock worth $493,000 after buying an additional 277 shares during the period. Sivia Capital Partners LLC raised its stake in Procter & Gamble by 19.8% during the second quarter. Sivia Capital Partners LLC now owns 6,144 shares of the company’s stock worth $979,000 after buying an additional 1,016 shares during the last quarter. Auxano Advisors LLC lifted its holdings in Procter & Gamble by 10.8% in the second quarter. Auxano Advisors LLC now owns 7,315 shares of the company’s stock valued at $1,165,000 after buying an additional 714 shares during the period. Finally, Schnieders Capital Management LLC. lifted its holdings in Procter & Gamble by 2.8% in the second quarter. Schnieders Capital Management LLC. now owns 30,182 shares of the company’s stock valued at $4,809,000 after buying an additional 809 shares during the period. 65.77% of the stock is owned by institutional investors and hedge funds.

Procter & Gamble Trading Down 0.2%

PG opened at $144.19 on Thursday. The company has a fifty day moving average price of $153.85 and a two-hundred day moving average price of $149.84. Procter & Gamble Company has a 1-year low of $137.62 and a 1-year high of $174.80. The company has a market cap of $335.10 billion, a P/E ratio of 21.36, a price-to-earnings-growth ratio of 5.08 and a beta of 0.41. The company has a current ratio of 0.72, a quick ratio of 0.51 and a debt-to-equity ratio of 0.49.

Procter & Gamble (NYSE:PG) last released its quarterly earnings data on Friday, January 23rd. The company reported $1.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.02. The company had revenue of $22.21 billion for the quarter, compared to analysts’ expectations of $22.36 billion. Procter & Gamble had a net margin of 19.30% and a return on equity of 32.21%. The business’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.88 EPS. Analysts predict that Procter & Gamble Company will post 6.91 EPS for the current fiscal year.

Procter & Gamble Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, February 17th. Shareholders of record on Friday, January 23rd were paid a $1.0568 dividend. This represents a $4.23 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Friday, January 23rd. Procter & Gamble’s dividend payout ratio (DPR) is 62.67%.

Procter & Gamble News Summary

Here are the key news stories impacting Procter & Gamble this week:

• Positive Sentiment: Investors are rotating into defensive, dividend-rich consumer staples as recession odds rise, which supports demand for PG stock as a low-beta hedge. As Recession Odds Climb, Defensive Sectors Continue to Outperform (PG)
• Positive Sentiment: New OLAY peptide research was presented at a dermatology conference and P&G plans to integrate proprietary peptide technologies into product formulas—an R&D catalyst that could support premium pricing and brand value over time. OLAY Peptide Research Puts New Spotlight On Procter And Gamble Valuation
• Positive Sentiment: Recent session saw PG outperform the market on a prior close, reflecting investor preference for staples amid broader weakness. This shows defensive demand can provide near-term support. Procter & Gamble (PG) Ascends While Market Falls
• Neutral Sentiment: Analysts expect P&G’s upcoming fiscal Q3 results to show low single-digit EPS growth—this raises the bar modestly: a beat could lift the stock, while a slight miss may reinforce current caution. What to Expect From Procter & Gamble’s Next Quarterly Earnings Report
• Neutral Sentiment: Market commentary and analyst notes on consumer goods (including P&G and peers) are circulating, offering mixed takes that could influence near-term analyst revisions but contain no single decisive catalyst. Analysts Offer Insights on Consumer Goods Companies: Procter & Gamble (PG) and Costco (COST)
• Negative Sentiment: TD Cowen cut its price target to $142 from $156 and kept a Hold rating, citing oil-related input-cost inflation tied to geopolitical tensions—this analyst action puts downward pressure on sentiment and could limit near-term upside. TD Cowen Adjusts Price Target on Procter & Gamble to $142 from $156; Maintains Hold Rating
• Negative Sentiment: Reports say Deutsche Bank has lowered expectations for P&G, and coverage notes broadly point to cost pressures (including oil-related input inflation from Middle East tensions) that could compress margins if raw-material costs accelerate. Deutsche Bank Aktiengesellschaft Has Lowered Expectations for Procter & Gamble (NYSE:PG) Stock Price
• Negative Sentiment: Coverage summarizing analyst downgrades highlights Iran-war related cost risks and has contributed to recent negative headlines and downgrades that weigh on sentiment. Wall Street Downgrades Procter & Gamble Amid Iran War Cost Pressures and More

Analyst Upgrades and Downgrades

PG has been the subject of a number of recent analyst reports. Piper Sandler assumed coverage on Procter & Gamble in a report on Wednesday, January 7th. They set a “neutral” rating and a $150.00 price target for the company. Erste Group Bank downgraded Procter & Gamble from a “buy” rating to a “hold” rating in a research note on Tuesday, March 24th. Dbs Bank upgraded Procter & Gamble from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Rothschild & Co Redburn lifted their target price on Procter & Gamble from $155.00 to $157.00 and gave the stock a “neutral” rating in a report on Friday, January 23rd. Finally, BNP Paribas Exane dropped their price target on Procter & Gamble from $172.00 to $164.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. Twelve equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $167.06.

Insider Activity

In related news, CEO Gary A. Coombe sold 36,093 shares of Procter & Gamble stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $162.33, for a total value of $5,858,976.69. Following the completion of the sale, the chief executive officer owned 34,994 shares of the company’s stock, valued at approximately $5,680,576.02. This trade represents a 50.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Chairman Jon R. Moeller sold 162,232 shares of the business’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $162.45, for a total transaction of $26,354,588.40. Following the sale, the chairman owned 319,385 shares of the company’s stock, valued at $51,884,093.25. This trade represents a 33.68% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 348,618 shares of company stock valued at $55,462,643. Corporate insiders own 0.20% of the company’s stock.

Procter & Gamble Company Profile

Procter & Gamble (NYSE: PG) is a multinational consumer goods company headquartered in Cincinnati, Ohio. Founded in 1837 by William Procter and James Gamble, P&G has grown into one of the world’s largest producers of branded consumer packaged goods. The company focuses on developing, manufacturing and marketing a broad portfolio of household and personal care products sold to consumers and retailers worldwide.

P&G’s product offering spans several core business categories, including Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care.